Consensus Conference to Assess Adjuvant Therapy for Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

BETHESDA, Md-The National Institutes of Health will convene a consensus development conference on adjuvant therapy for breast cancer on November 1–3, 2000.

BETHESDA, Md—The National Institutes of Health will convene a consensus development conference on adjuvant therapy for breast cancer on November 1–3, 2000.

The meeting will consider new information on chemotherapy, hormonal therapy, and other treatment aspects, including the clinical use of prognostic markers and quality-of-life issues. A panel of experts from outside NIH will make recommendations after hearing 2 days of presentations by leading researchers. The last breast cancer consensus conference on adjuvent therapy was in 1990.

Articles in this issue
IL-13 Used to Deliver Bacterial Toxin to Brain Tumors in Mice
BAG-1 Overexpression Has a ‘Paradoxical’ Association With Improved Breast Cancer Survival
Rituximab/CHOP Combo Effective in Low-Grade NHL
3D CT-Guided Seminal Vesicle Biopsy for Staging
Elderly Patients Tolerate Breast Cancer Therapy
Coaxial Breast Biopsy Device Provides Diagnostic Specimens
3D Digital Camera Accurately Calculates Breast Shape, Volume
Thermoacoustic CT Under Development for Breast Imaging
Early Local Recurrence After Lumpectomy Predicts Metastasis
Panel Recommends Listing 9 Substances in Carcinogen Report
State of the Union on Youth Smoking ‘Clearly Not Good’
Low-Dose CT Screening Detects NSCLC: ELCAP Update
Mandatory HIV Testing of Newborns Not Routine: HHS
ASCO Launches Large-Scale Study on Quality of Cancer Care
Advocate Urges Greater Attention to Cancer Prevention Research
Recent Videos
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content
Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.

Patient-Reported Outcomes Support Sacituzumab Govitecan Combo in TNBC

Kristie L. Kahl
October 23rd 2025
Article

Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Policies aimed at improving health coverage and financial assistance may help improve treatment affordability to ensure more equitable survival.

Data Show Growing Trend in Insurance/Racial OS Disparities in Breast Cancer

Roman Fabbricatore
October 20th 2025
Article

Policies aimed at improving health coverage and financial assistance may help improve treatment affordability to ensure more equitable survival.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.

Subgroup Analysis Yields Clinically Meaningful Responses With T-DXd in HER2+ Breast Cancer

Ariana Pelosci
October 19th 2025
Article

T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.

Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.

Sacituzumab Tirumotecan Prolongs PFS Vs Chemo in Pretreated Breast Cancer

Andrea Eleazar, MHS
October 19th 2025
Article

Data from OptiTROP-Breast02 support sac-TMT as a new treatment option for those with hormone receptor–positive, HER2-negative breast cancer.